Last update 08 Aug 2026

DCC-2812

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DCC-2812
Target
EIF2AK4
Action
stimulants
Mechanism
EIF2AK4 stimulants(eukaryotic translation initiation factor 2 alpha kinase 4 stimulants)
Therapeutic Areas
NeoplasmsUrogenital Diseases
Active Indication
Castration-Resistant Prostatic CancerMetastatic Renal Cell CarcinomaUrothelial Carcinoma of the Urinary Bladder
Inactive Indication-
Originator Organization
Deciphera Pharmaceuticals, Inc.Deciphera Pharmaceuticals, Inc.
Active Organization
Deciphera Pharmaceuticals, Inc.Deciphera Pharmaceuticals, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with DCC-2812
NCT06966024
/ RecruitingPhase 1
An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
100 Clinical Results associated with DCC-2812
Login to view more data
100 Translational Medicine associated with DCC-2812
Login to view more data
100 Patents (Medical) associated with DCC-2812
Login to view more data
100 Deals associated with DCC-2812
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Castration-Resistant Prostatic CancerPhase 1
United States
Deciphera Pharmaceuticals, Inc.Deciphera Pharmaceuticals, Inc.
27 Aug 2025
Metastatic Renal Cell CarcinomaPhase 1
United States
Deciphera Pharmaceuticals, Inc.Deciphera Pharmaceuticals, Inc.
27 Aug 2025
Urothelial Carcinoma of the Urinary BladderPhase 1
United States
Deciphera Pharmaceuticals, Inc.Deciphera Pharmaceuticals, Inc.
27 Aug 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT06966024 (ASCO2026)
Phase 1
Renal Cell Carcinoma | Urogenital Neoplasms | Castration-Resistant Prostatic Cancer ...
View more
32
(Advanced Genitourinary Cancers)
ioboepqeze(vllehjndte) = embbhmqmho ebupllqujx (nkqlrimwfd, 2.8 - NE)
Positive
29 May 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free